These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35707213)

  • 1. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
    Jiménez JL
    J Appl Stat; 2022; 49(2):466-484. PubMed ID: 35707213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
    Huang B; Kuan PF
    Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
    Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
    JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic RMST curves for survival analysis in clinical trials.
    Liao JJZ; Liu GF; Wu WC
    BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential tests for non-proportional hazards data.
    Brückner M; Brannath W
    Lifetime Data Anal; 2017 Jul; 23(3):339-352. PubMed ID: 26969674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of treatment effects in weighted log-rank tests.
    Lin RS; León LF
    Contemp Clin Trials Commun; 2017 Dec; 8():147-155. PubMed ID: 29696204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
    Yang S
    Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
    Jiménez JL; Stalbovskaya V; Jones B
    Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust group sequential designs for trials with survival endpoints and delayed response.
    Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
    Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of Restricted Mean Survival Time Based Methods and Traditional Survival Methods: An Application in an Oncological Data.
    Huang Q; Tian C
    Comput Math Methods Med; 2022; 2022():7264382. PubMed ID: 36619796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partitioned log-rank tests for the overall homogeneity of hazard rate functions.
    Liu Y; Yin G
    Lifetime Data Anal; 2017 Jul; 23(3):400-425. PubMed ID: 26995734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials.
    Lu Y; Tian L
    Stat Biopharm Res; 2021; 13(2):210-218. PubMed ID: 33927801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex survival trial design by the product integration method.
    Tang Y
    Stat Med; 2022 Feb; 41(4):798-814. PubMed ID: 34908180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect.
    Yu C; Huang X; Nian H; He P
    Pharm Stat; 2021 May; 20(3):528-550. PubMed ID: 33427400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
    Rauch G; Brannath W; Brückner M; Kieser M
    Methods Inf Med; 2018 May; 57(3):89-100. PubMed ID: 29719915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new modeling and inference approach for the Systolic Blood Pressure Intervention Trial outcomes.
    Yang S; Ambrosius WT; Fine LJ; Bress AP; Cushman WC; Raj DS; Rehman S; Tamariz L
    Clin Trials; 2018 Jun; 15(3):305-312. PubMed ID: 29671345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.
    Quartagno M; Morris TP; Gilbert DC; Langley RE; Nankivell MG; Parmar MK; White IR
    Clin Trials; 2023 Dec; 20(6):594-602. PubMed ID: 37337728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.